Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the efficacy and safety of adding Symlin (pramlintide) to insulin glargine (Lantus) in subjects with type 2 diabetes; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)
• Symlin (pramlintide)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED